ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae147 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Muhammad Bilal Mirza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Gene Amplification, Health Status Disparities, Erb-b2 Receptor Tyrosine Kinases, Stomach Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH, NICHD NIH HHS, NIH HHS.
Abstract (Originalsprache)
Overall, gastric adenocarcinoma (GC) incidence rates have declined in recent years, but racial and ethnic disparities persist. Individuals who identify as Hispanic/Spanish/Latino are diagnosed with GC at younger ages and have poorer outcomes than non-Hispanic individuals. However, our understanding of GC biology across racial/ethnic groups remains limited. We assessed tumor genomic patterns by race/ethnicity among 1019 patients with primary GC in the American Association for Cancer Research (AACR) Project GENIE Consortium. Hispanic individuals presented with significantly higher rates of ERBB2/HER2 amplification vs other racial/ethnic groups (Hispanic: 13.9% vs 9.8% non-Hispanic White, 8.1% non-Hispanic Asian, and 11.0% non-Hispanic Black; P < .001, FDR adjusted q < 0.001). Hispanic patients also had higher odds of an ERBB2 amplification vs non-Hispanic Whites in adjusted models (OR = 2.52, 95%CI = 1.20 to 5.33, P = .015). These findings underscore the important role of genomic factors in GC disparities. Ensuring equitable access to genomic profiling and targeted therapies, such as trastuzumab for HER2-overexpressing GC, is a promising avenue to mitigate GC disparities and improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
- Division of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
- Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
- Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
- GI Section, VA San Diego Health System, La Jolla, CA, USA.
- Division of Gastroenterology, Department of Medicine, University of California, San Diego, CA, USA.
ORCID-Profile: Muhammad Bilal Mirza, Xingyi Guo, Kamran Idrees
Förderung
- NIH
- NICHD NIH HHS
- NIH HHS
- NCI NIH HHS
- CSRD VA
- National Institutes of Health
- NICHD
- National Cancer Institute
Zitieren
APA
Mirza, M. B., Choi, J., Marincola Smith, P., Baechle, J. J., Padmanabhan, C., Holowatyj, A. N., Shah, S. C., Guo, X., & Idrees, K. (2024). ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae147
Vancouver
Mirza MB, Choi J, Marincola Smith P, Baechle JJ, Padmanabhan C, Holowatyj AN, et al. ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae147
BibTeX
@article{Mirza2024,
author = {Mirza, Muhammad Bilal and Choi, Jungyoon and Marincola Smith, Paula and Baechle, Jordan J and Padmanabhan, Chandrasekhar and Holowatyj, Andreana N and Shah, Shailja C and Guo, Xingyi and Idrees, Kamran},
title = {ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae147}
}
EUVIMED